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Abstract
Background: Angiogenin (ANG), a component of tears, is involved in the innate immune system and is related
with inflammatory disease. We investigated whether ANG has an immune modulatory function in human corneal
fibroblasts (HCFs).
Methods: HCFs were cultured from excised corneal tissues. The gene or protein expression levels of
interleukin (IL)-1beta (β), IL-4, IL-6, IL-8, IL-10, complements, toll-like receptor (TLR)4, myeloid differentiation
primary response gene (MYD)88, TANK-binding kinase (TBK)1, IkappaB kinase-epsilon (IKK-ε) and nuclear
factor-kappaB (NF-κB) were analyzed with or without ANG treatment in tumor necrosis factor-alpha (TNF-α)-
or lipopolysaccharide (LPS)-induced inflammatory HCFs by real-time polymerase chain reaction (PCR), Western
blotting and immunocytochemistry. Inflammatory cytokine profiles with or without ANG were evaluated
through immunodot blot analysis in inflammatory HCFs. Corneal neovascularization and opacity in a rat
model of corneal alkali burn were evaluated after application of ANG eye drops.
Results: ANG decreased the mRNA levels of IL-1β, IL-6, IL-8, TNF-α receptor (TNFR)1, 2, TLR4, MYD88, and
complement components except for C1r and C1s and elevated the mRNA expression of IL-4 and IL-10.
Increased signal intensity of IL-6, IL-8 and monocyte chemotactic protein (MCP)-1 and MCP-2 induced by
TNF-α or LPS was weakened by ANG treatment. ANG reduced the protein levels of IKK-ε by either TNF-α and
LPS, and decreased TBK1 production induced by TNF-α, but not induced by LPS. The expression of NF-κB in
the nuclei was decreased after ANG treatment. ANG application lowered corneal neovascularization and
opacity in rats compared to controls.
Conclusion: These results demonstrate that ANG reduces the inflammatory response induced by TNF-α or
LPS in HCFs through common suppression of IKK-ε-mediated activation of NF-κB. This may support the
targeting of immune-mediated corneal inflammation by using ANG.
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Background
The cornea, the transparent part of the eye, performs a
significant function in eyesight by refracting the light to
focus a visual image. As the cornea is indispensable for
vision, corneal inflammation may induce visual disturb-
ance and blindness. Several investigations have reported
that various corneal inflammatory diseases cause visual
impairment and chronic inflammation of the cornea can
lead to blindness [1, 2]. It is well documented that
chronic inflammation of human corneal fibroblasts
(HCFs) leads to several corneal diseases including cor-
neal opacity and ulceration, and these conditions lead to
vision impairment in severe cases [3].
Although the human cornea is an immune privileged
site in the body, chronic immune mediated inflammation,
such as chemical burns or herpetic stromal keratitis, occa-
sionally occurs in the corneal stroma, and HCFs residing
in the corneal stroma conduct an important role in the
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regulation of local immune and inflammatory response
[4]. HCFs also regulate the production of cytokines and
play a role in the control of stromal inflammation [5, 6]. It
has been reported that HCFs secrete pro-inflammatory
cytokines and chemokines including interleukin (IL)-6
and IL-8 in response to inflammatory stimuli [4, 5, 7].
Moreover, HCFs modulate complement activation in di-
verse immune responses. For instance, in a healthy human
eye, HCFs synthesize complement components and the
complement cascade is activated chronically at a low level,
but complement component 3 (C3) and C5 production is
up-regulated by several cytokines [8, 9]. The complement
system is an important part of innate immunity and its ac-
tivation plays a major role in the inflammatory response.
It has been widely accepted that complement activation
causes inflammation via nuclear translocation of nuclear
factor-kappaB (NF-κB) [10]. The activation of the comple-
ment system in the normal human eyes is initiated by the
immune response and it induces advancement of corneal
inflammation [11]. As one of the mechanisms, it has been
suggested that complement activation is triggered by in-
flammatory stimuli such as tumor necrosis factor-alpha
(TNF-α) or lipopolysaccharide (LPS) [12, 13].
TNF-α is a cytokine that induces inflammatory responses
and binds to two receptors, TNF-α receptor (TNFR)1 and
TNFR2. It has been demonstrated that TNF-α plays a crit-
ical role in corneal inflammation [14]. LPS released from
gram-negative bacteria induces innate immune response by
binding to the toll like receptor (TLR)4 and the activation
of TLR4 causes pro-inflammatory cytokines production
such as IL-6 and IL-8 in the cornea [15]. It is well known
that LPS provokes inflammation in the cornea [16]. TNF-α
and LPS promote the nuclear translocation of NF-κB and
activate NF-κB signaling pathway, which is indispensable in
all mammalian cell types and controls several genes in-
volved in immune-inflammatory responses [17–19].
The nuclear translocation of NF-κB related to the in-
flammatory response is inhibited by regulatory protein
IkappaB (IκB), which normally prevents nuclear trans-
location of NF-κB by arresting it in the cytoplasm [20].
In the activation of NF-κB and the downstream tran-
scription, IκB kinase epsilon (IKK-ε) and TANK-binding
kinase (TBK)1 are known as the promoters [21, 22]. The
activation of IKK-ε causes secretion of pro-inflammatory
cytokines and the sequence of IKK-ε showed 49 % hom-
ology with the sequence of TBK1, which mediates NF-
κB signaling pathway in inflamed HCFs [23, 24]. TNF-α
and LPS cause activation of IKK-ε and TBK1 by indu-
cing inflammation through the nuclear translocation of
NF-κB, in contrast, an inhibitor of IKK-ε and TBK1 has
the potential to decrease inflammation [20, 25].
Angiogenin (ANG) is a 14.4 kDa single chain protein
containing 123 amino acids and the expression of ANG is
associated with an inflammatory response. It has been
reported that ANG levels were increased in serum of in-
flammatory bowel disease patients [26]. The mRNA expres-
sion and protein levels of ANG are increased in an
inflammatory environment such as treatment with TNF-α
and IL-1β [27, 28]. Previous evidences have been demon-
strated that ANG has the potential to influence innate im-
mune modulation. It has long been recognized that ANG is
a microbial protein involved in innate immunity and has
bactericidal activity [29]. ANG is also known as a compo-
nent of the tear fluid and plays an important role in pro-
tecting the ocular surface as it is an antimicrobial peptide
[30]. In our previous report, it was well documented that
ANG down-regulates pro-inflammatory cytokines expres-
sion through inhibition of TBK1 production in HCFs [24].
The present study was performed to investigate the
anti-inflammatory activity of ANG in the cornea. First,
we investigated the anti-inflammatory effect of ANG
using a rat model of corneal alkali burn in vivo. Second,
we studied the anti-inflammatory activity of ANG, which
inhibits the expression of pro-inflammatory cytokines,
chemokines and complement components during the
corneal inflammatory process. Finally, in order to under-
stand how ANG reduces the inflammatory response, we
undertook to elucidate its effect on the NF-κB pathway
mediated by IKK-ε in TNF-α- or LPS-induced inflamma-
tory HCFs.
Methods
Animal model for corneal alkali burn
Twenty healthy adult male Sprague Dawley rats (weight
range, approximately 250–270 g) were selected for this in-
vestigation. The animals were initially examined and
screened for any preexisting ophthalmic lesions. The rats
were anesthetized via intramuscular injection of 0.05 cc/
50 g of tiletamine plus zolazepam (Zoletil™, Virbac, Fort
Worth, TX, USA) and 0.05 cc/100 g of xylazine (Rompun™,
Bayer, Leverkusen, Germany). Alkali burn was induced in
the right eye by 60 s of exposure of the corneal periphery
including limbus to a 4 mm diameter disk of filter paper
soaked in 1 N NaOH rinsing with sterile saline. The control
group (n = 10) was treated topically with 10 μl of PBS, and
the treatment group (n = 10) was treated with 10 μl of
ANG (50 μg/ml) eye drops four times a day immediately
after the alkali injury. The treatments were administered
daily at the same time for a total period of 56 days.
Evaluation of corneal opacity and neovascularization
The corneal opacity was measured using the scoring sys-
tem [31] to evaluate the degree of corneal opacification
between 0 to +4. The area of corneal neovascularization
was quantified from the photographs based on the ratio of
total corneal area using Image J software and previously
established formula such as A = C/12 x 3.1416 [r2- (r -l)2]
(A : The area of corneal neovascularization, C : the
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number of clock hour, r : Radius of rat cornea, l : Reticule
the vessel length) [32]. The mean differences in corneal
opacities and corneal NV area were compared between
the control group and ANG treatment group.
Isolation and primary culture of human corneal fibroblast
cells
Human corneal donor tissues were obtained during
penetrating keratoplasty. The method of isolation and
primary culture of HCFs was described in a previous
article [24]. In briefly, the corneal epithelium was elimi-
nated and then the corneal fibroblast cells were de-
tached from the explant tissue. The corneal tissues
were rinsed with phosphate-buffered saline (PBS)
mixed with 5 % penicillin-streptomycin and cut into
explants of approximately 1 mm3. The HCFs were then
subcultured by trypsin digestion and cultured in alpha-
minimum essential medium (α-MEM) (Invitrogen,
Waltham, MA, USA) containing 10 % FBS and 1 %
penicillin-streptomycin. The cells were maintained at
37 °C under 5 % CO 2 and used for experiments after
three to five passages.
Cell treatment
HCFs were cultured in six-well plates for 3 days. The cells
were washed twice with PBS. The medium containing the
confluent corneal fibroblast cells was changed to serum-
free MEM for 1 day before treatment. The cells were
treated with TNF-α (20 ng/ml) purchased from ProSpec
(Ness-Ziona, Israel) for eight hours or LPS (1 μg/ml) pur-
chased from Sigma-Aldrich (St. Louis, MO, USA) for four
hours, and with or without ANG (2 μg/ml) for 30 min.
ANG was obtained from the Department of Biochemistry
at Chungbuk National University in Korea and the identity
of the purified ANG was confirmed by Western blotting
with ANG-specific antibodies with methods described in a
previous report [33]. The biological activity of the purified
ANG also was confirmed by its nuclear translocation in
human umbilical vein endothelial cells by a procedure
previously described in detail [33]. The purification and
endotoxin levels of recombinant ANG expressed in E. coli
are described previously [24]. The cells were then collected
for total RNA isolation and protein extraction.
RNA isolation and real-time RT-PCR
Total RNA was isolated from cultured HCFs using rat cor-
neal tissue and FavorPrep™ Tri-RNA reagent (Favorgen
Biotech Corp., Ping-Tung, Taiwan) according to the manu-
facturer’s protocols. The quantity and quality of the RNA
was determined using a NanoDrop ND-1000 spectropho-
tometer (Nano-Drop Technologies, Inc. Wilmington, DE,
USA). Single-stranded complementary DNA (cDNA) was
synthesized from 500 ng of total RNA using a cDNA syn-
thesis kit (Takara Bio, Inc., Otsu, Japan). Real-time RT-PCR
was conducted using the CFX96TM Real-Time PCR Detec-
tion System (Bio-Rad Laboratories, Inc., Hercules, CA,
USA) in a total volume of 20 μL containing 10 μL of SYBR
Premix Ex Taq (Takara Bio, Inc.), diluted cDNA template,
and forward and reverse primers. The primer sequences
and product sizes are listed in Table 1. PCR amplification
for the selected genes was run for 40 cycles. Gene expres-
sion was analyzed by real-time reverse transcriptase poly-
merase chain reaction (PCR). Real-time PCR quantification
was performed in triplicate for each sample and the mean
was calculated. Expression levels were analyzed by real-
time PCR using values of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) as a reference.
Immunodot blot assay
The expression of 42 human cytokines and chemo-
kines was assessed using a commercially available
cytokine assay (RayBio Human Cytokine Antibody
Array three, RayBiotech, Norcross, GA, USA) that uti-
lizes membrane-bound cytokine-specific antibodies to
assess for the presence of several cytokines in bio-
logical fluids. The analysis was conducted according to
the manufacturer’s instructions. Briefly, membranes were
blocked for 30 min and then incubated with HCF culture
supernatant for two hours at room temperature. The
membranes were washed with Wash Buffer I three times
for 5 min each and then with Wash Buffer II twice for
5 min each. After washing, the membranes were incu-
bated with a biotin-conjugated antibody mix for two
hours, and then streptavidin-conjugated peroxidase was
added for two hours at room temperature. The mem-
branes were subsequently washed thoroughly and exposed
to chemiluminescence. The membranes were visualized
using the ECL Plus detection system and ChemiDocTM
XRS (Bio-Rad Laboratories Inc.). The densities for individ-
ual spots were calculated using Image J software (National
Institutes of Health, USA). The relative expression ratio
was determined by subtraction of the background signal
and comparison with positive controls on the membrane.
Positive controls visible within each array were used for
comparison.
Nuclear and cytosolic protein extractions
HCFs were washed and scraped with cold PBS. The cells
were lysed in buffer A (10 mM HEPES [pH 7.9], 10 mM
KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM
PMSF, 5 μg/ml Leupeptin) and left on ice for 15 min.
After 10 % NP-40 was added to the sample, the cytosolic
fraction was collected by centrifugation at 14,000 rpm for
5 min at 4 °C. The nuclear fraction was re-suspended in
buffer C (20 mM HEPES [pH7.9], 0.4 n NaCl, 1 mM
EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF, 10 μg/ml
Leupeptin) and left on ice for 30 min, and then the
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nuclear fraction was collected by centrifugation at
14,000 rpm for 5 min at 4 °C.
Western blot analysis
Total cellular protein was isolated from cultured cells
with a protein extraction solution (PRO-PREP, iNtRON
biotechnology, Inc., Seongnam-si, Gyeonggi-do, Korea).
Nuclear proteins and total cell lysates were separated by
10 % sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) and electrophoretically transferred
to a polyvinylidene fluoride membrane (PVDF; Merck
Millipore, Billerica, MA, USA) at 100 V (1 h, 4 °C) in
buffer containing 0.3 % Tris, 1.4 % glycine, and 20 %
methanol using a wet-blotting apparatus (Mini-PRO-
TEANTetra cell; Bio-Rad Laboratories, Inc.). The PVDF
membrane containing the transferred proteins was
blocked with 5 % BSA in PBS for one hour at room
temperature. Primary monoclonal antibodies against hu-
man IKK-ε (Abcam, Cambridge, MA, USA), TBK1
(Abcam), and NF-κB (Bioworld Technology, Inc., St.
Louis, MN, USA) diluted in PBS (1:1000) was applied to
the PVDF membrane and incubated overnight at 4 °C.
Secondary antibodies diluted in PBS (1:2000) were subse-
quently applied to the PVDF membrane and incubated for
1 h at room temperature. The PVDF membrane was
washed four times (10 min each) with Tris-buffered saline
(TBS; 50 mM Tris HCl pH 7.5, 150 mM NaCl) containing
0.1 % Tween 20. The binding of specific antibodies was
visualized using an enhanced chemiluminescence Western
blotting detection kit (Pierce Biotechnology, Inc., Rockford,
IL, USA). Densitometric quantification of the immunoblot
was carried out using ImageJ software. The value of each
band was normalized to β-actin or lamin.
Immunocytochemistry
The HCFs cultured on glass slides were treated with
TNF-α (20 ng/ml) for eight hours or with LPS pur-
chased from Sigma-Aldrich (1 μg/ml) for four hours.
Cells were also treated with or without ANG (2 μg/ml)
for 30 min. Cells were then fixed in 4 % paraformalde-
hyde for 15 min at room temperature. After being
permeabilized by incubation with 0.5 % Triton X-100 for
15 min at room temperature, the slides were incubated
with anti-NF-κB (diluted to 1:50 in PBS, Bioworld Tech-
nology, Inc.) for 1 h at room temperature. Glass slides
were incubated with secondary antibody for 1 h at room
temperature. At each step, the slides were washed three
times (5 min each) with PBS. Cover slips were mounted
on the slides using Vectashield (Vector Laboratories,
Burlingame, CA, USA) containing 40,6-diamidino-2-
phenylindole (DAPI).
Statistical analysis
Data are expressed as the mean ± standard error (SE).
Statistical analysis of three separate experiments was
conducted using one-way ANOVA followed by a post
Table 1 Sequences of PCR primers
Gene Sense primer (5’→3’) Anti-sense primer (3’→5’) Product size (bp)
GAPDH CGAGATCCCTCCAAAATCAA TGTGGTCATGAGTCCTTCCA 294
IL-1β CCTGTCCTGCGTGTTGAAAGA GGGAACTGGGCAGACTCAAA 150
IL-4 AACACAACTGAGAAGGAAACCTTC GCTCGAACACTTTGAATATTTCTC 276
IL-6 TTCGGTCCAGTTGCCTTCTC GAGGTGAGTGGCTCTCTGTG 112
IL-8 ACATGACTTCCAAGCTGGCCG TTTATGAATTCTCAGCCCTC 302
IL-10 GCCTAACATGCTTCGAGATC TGATGTCTGGGTCTTGGTTC 206
TLR4 AGCCTAAGCCACCTCTCTACCT AGATTTGTCTCCACAGCCACCA 116
MYD88 ATGGTGGTGGTTGTCTCTGATG GACAGGATGAACCTCAGGATGC 165
TNFR1 GTGCTGTTGCCCCTGGTCAT GCTTAGTAGTAGTTCCTTCA 163
TNFR2 AAACTCAAGCCTGCACTC GGATGAAGTCGTGTTGGAGA 209
C1r CAACAACTTTGAAACAACCA GGAGAAGTCTGTGTGGAAGG 237
C1s AAGTCAGACTTTTCCAATGA ACTTGCAATCTCCCCAATCA 247
C2 TGGAGTGGACAAGCTGTGCCG TGAAAGTCTCGTGGCGGCGG 289
C3 TGGCTGTTCGCACCCTGGAT AGCCCGAGGGGGTCACAATGA 204
C4 ATGGTTCCTATGCGGCTTGGTTGTC GCGATGGTCACAAAGGCTGTGAGTG 256
C5 TGGCAACCAGCTCCAGGTTCAT TGCCCCACAGCCCAGATCACT 208
CFB CAAGAAGGCCCTCCAGGCAGT AAGGCCCGACCCCAAACACAT 233
TBK1 TTCTGGAAGTCCATACGCAT ACTGGTGATCTCTATGCTGT 237
IKK-ε CTGCTCATGAATGACAGTGA GGCGAGTGTATGTTATGCTT 132
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hoc pairwise comparison adjusted with a Bonferroni cor-
rection and analysis of two separate was performed
using Mann–Whitney U test. Statistical analyses were
performed using the SPSS software version 19.0 (SPSS
Inc., Chicago, IL, USA). Differences were considered sta-
tistically significant at p < 0.05.
Results
ANG improves corneal inflammation in in vivo rat models
with alkali burn
ANG-treated eyes of rat models almost recovered their
normal corneal transparency and showed a significant re-
duction in the corneal opacity score compared to the
Fig. 1 Comparison of corneal opacity and neovascularization in rat corneas with alkali burn between the angiogenin (ANG) group and the
control group. a Representative photographs demonstrated the corneal surface on day 3 and 56 after injury. Marked corneal opacity (arrow) was
noted by day 56 after injury, and significant neovascularization (arrow head) developed by day 56 after injury to the cornea in the control group.
In contrast, the clear transparent cornea (inside large black circle) and clear papillary margin (small black circle) in the ANG-treated cornea is noted.
b Quantification of corneal opacity following a clinical grading system on a scale from 0 to +4 and quantification of corneal neovascularization.
Corneal opacity and neovascularization were significantly down-regulated by ANG administration. Quantified estimates of corneal neovascularization
are expressed as relative ratio of the neovascularizaed area to the whole corneal area. Values represent the mean ± standard error. Mann–Whitney U
test, *p < 0.05
Fig. 2 Real-time PCR analyses of pro-inflammatory and anti-inflammatory cytokines in human corneal fibroblasts (HCFs) with or without
angiogenin (ANG) treatment. a The increased relative mRNA levels of IL-1β, IL-6 and IL-8 by tumor necrosis factor-alpha (TNF-α) or
lipopolysaccharide (LPS) were diminished by ANG treatment. b The relative mRNA levels of IL-4 and IL-10 were increased by ANG
treatment. The experiments were repeated at least three times. Values represent the mean ± standard error. One-way ANOVA followed
by Bonferroni’s post hoc analysis, *p < 0.05
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control eyes at 14 days after alkali injury. Until 2 months
after alkali burn in rat models, ANG eye drops signifi-
cantly improved the signs of alkali-induced representative
corneal inflammation such as corneal opacity and neovas-
cularization at the peripheral cornea, including conjunc-
tiva compared to that in controls (Fig. 1a and b). Corneal
Fig. 3 Immunodot blot analysis of inflammatory cytokine profiles in culture medium of human corneal fibroblasts (HCFs) with or without
angiogenin (ANG) treatment. a Treatment of HCFs with tumor necrosis factor-alpha (TNF-α, 20 ng/ml) resulted in amplification of five inflammatory
cytokines and chemokines including growth regulated oncogene (GRO), TNF-α, interleukin (IL)-6, IL-8, and monocyte chemotactic protein (MCP)-1.
Treatment of HCFs with lipopolysaccharide (LPS, 1 μg/ml) resulted in amplification of five inflammatory cytokines and chemokines including GRO, TNF-
α, IL-6, IL-8, and MCP-1. Treatment of HCFs with ANG (2 μg/ml) resulted in reduction in expression of these inflammatory cytokines and chemokines. b
Cytokine Antibody Array Map. Pos: positive control; Neg: negative control; ENA: epithelial neutrophil-activating protein; GCSF: granulocyte colony-
stimulation factor; GM-CSF: granulocyte macrophage CSF; IFN-γ: interferon-gamma; MCSF: macrophage CSF; MDC: monocyte chemotactic protein;
MIG: monokine induced by IFN-γ; MIP: macrophage inflammatory protein; RANTES: Regulated on Activation, Normal T Cell Expressed and Secreted;
SCF: stem cell factor; SDF-1: stromal cell derived factor-1; TARC: thymus and activation-regulated chemokine; TGF-β1: transforming growth factor-beta1;
EGF: epidermal growth factor; IGF-1: insulin-like growth factor; VEGF: vascular endothelial growth factor; PDGF: platelet-derived growth factor. c Relative
density of inflammatory cytokines and chemokines. The values presented in the bar graph are the mean ± standard error from triplicate experiments.
One-way ANOVA followed by Bonferroni’s post hoc analysis, *p < 0.05 versus TNF-α without ANG; #p < 0.05 versus LPS without ANG
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epithelial erosions were recovered at 3 days and did not
recur until 2 month-follow up in both control and ANG-
treated groups.
ANG inhibits pro-inflammatory cytokines and enhances
anti-inflammatory cytokines in HCFs
In order to determine whether ANG can reduce the in-
flammatory responses in HCFs, TNF-α or LPS was added
to the culture media to induce inflammation and then cells
were cultured in the presence or absence of ANG. Real-
time PCR was performed to investigate the effects of ANG
treatment on the mRNA expression of pro-inflammatory
(IL-1β, IL-6 and IL-8) and anti-inflammatory cytokines
(IL-4 and IL-10). The mRNA expression of IL-1β, IL-6 and
IL-8 induced by TNF-α or LPS treatment was decreased
significantly in HCFs when treated with ANG (Fig. 2a).
Moreover, the mRNA expression of anti-inflammatory cy-
tokines (IL-4 and IL-10) was increased significantly after
ANG treatment (Fig. 2b).
Immunodot blot assays were conducted to determine
whether ANG reduces inflammatory cytokines and
chemokines in media. Treatment with TNF-α or LPS pro-
moted the expression of inflammatory cytokines and che-
mokines such as IL-6 and IL-8, growth-related proteins
(GRO), GRO-α and monocyte chemotactic protein (MCP)-
1, MCP-2, monocyte chemotactic protein (MCSF),
oncostatin-M and TNF-α. Production of these cytokines
and chemokines at protein levels was downregulated in the
presence of ANG, but expression of ANG was self-up-
regulated by ANG treatment (Fig. 3a and b). We detected
significant differences when comparing media before and
after ANG treatment with respect to the presence of IL-6,
IL-8, MCP-1 and ANG in the medium obtained from
TNF-α-treated HCFs. In the medium obtained from LPS-
treated HCFs, ANG treatment significantly reduced the
production of GRO-α, IL-6, IL-8, MCP-1, MCP-2 and
TNF-α (Fig. 3c).
ANG reduces the expression of TNFR, TLR4, MYD88 and
complement components
Using real-time PCR, we determined whether ANG de-
creases mRNA level of TNFR1, TNFR2, TLR4, MYD88
and complement components. TNF-α treatment up-
regulated the mRNA expression of TNFR1 and TNFR2,
but a significant reduction was noted after ANG treat-
ment. ANG treatment also decreased TLR4 and MYD88
mRNA expression induced by LPS (Fig. 4).
The mRNA expression of complement components was
induced by TNF-α or LPS. After ANG treatment, the in-
creased mRNA expression of complement components
induced by TNF-α was reduced. All of the activated com-
plements influenced by LPS except for C1r and C1s were
inhibited by ANG at the mRNA level (Fig. 5).
ANG reduces IKK-ε and TBK1 production in HCFs stimu-
lated with LPS
The mRNA expression of IKK-ε and TBK1 was increased
by TNF-α or LPS. The ANG decreased the mRNA
Fig. 4 Real-time PCR analyses of tumor necrosis factor-alpha receptor (TNFR)1, TNFR2, toll-like receptor (TLR)4 and myeloid differentiation primary
response gene (MYD)88 in human corneal fibroblasts (HCFs) with or without angiogenin (ANG) treatment. a The relative mRNA level of TNFR1,
and TNFR2 was diminished by ANG treatment in HCFs stimulated with TNF-α. b The relative mRNA level of TLR4 and MYD88 was diminished by
ANG treatment in HCFs stimulated with lipopolysaccharide (LPS). The experiments were repeated at least three times. One-way ANOVA followed
by Bonferroni’s post hoc analysis, *p < 0.05
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expression of TBK1 and IKK-ε induced by TNF-α, and
decreased the mRNA expression of only IKK-ε which was
induced by LPS (Fig. 6a). According to Western blot ana-
lysis, TNF-α or LPS treatment increased IKK-ε and TBK1
expression in HCFs. TBK1 protein expression was down-
regulated in HCFs stimulated with TNF-α, but not in those
stimulated with LPS after ANG treatment on HCFs. IKK-ε
expression was reduced by ANG treatment in HCFs stimu-
lated with either TNF-α or LPS (Fig. 6b and c).
ANG inhibits nuclear translocation of NF-κB in HCFs
HCFs were cultured with either TNF-α or LPS and treated
with ANG to examine whether ANG reduces nuclear
translocation of NF-κB in HCFs. On Western blotting and
Fig. 5 Real-time PCR analyses of complement components in human corneal fibroblast (HCF) cells with or without angiogenin (ANG) treatment.
The relative mRNA level of complement components was diminished by ANG treatment in HCFs stimulated with tumor necrosis factor-alpha
(TNF-α). Except for C1r and C1s, levels of all complements were reduced by ANG treatment in lipopolysaccharide (LPS)-stimulated HCFs. The
experiments were repeated at least three times. One-way ANOVA followed by Bonferroni’s post hoc analysis, *p < 0.05
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immunofluorescent analysis, treatment of HCFs with TNF-
α or LPS increased the translocation of NF-κB from the
cytosol to the nucleus, on the contrary, ANG treatment
reversed the nuclear translocation of NF-κB into the cyto-
sol (Fig. 7).
Discussion
ANG which has been demonstrated extensively as an an-
giogenic molecule [34], also has antimicrobial activity and
is reported to be one of the tear components. This protein
is also known to be related to inflammatory diseases and
innate immunity. However, there is little mechanistic evi-
dence of the effect of ANG on the inflammatory response.
Here, we studied the anti-inflammatory activity of ANG
on inflamed HCFs via previously undiscovered novel
mechanisms.
The most meaningful finding of this study is that ANG
down-regulated TNF-α or LPS-induced inflammatory re-
sponse via suppression of IKK-ε expression. Several reports
have showed that the activation of IKK-ε leads to inflamma-
tion mediated by NF-κB [35, 36]. Moreover, it has been
demonstrated that the protein kinase IKK-ε regulates the
expression of inflammatory cytokines such as IL-6, -8,
MCP-1 and TNF-α [21, 37]. As the inhibition of IKK-ε ex-
pression is a well-known important property for reducing
inflammation, our result indicating the anti-inflammatory
Fig. 6 Real-time PCR analyses and Western blot analyses of TANK-binding kinase (TBK)1 and IkappaB kinase-epsilon (IKK-ε) in human corneal
fibroblast (HCF) cells with or without angiogenin (ANG) treatment. a The relative mRNA level of TBK1 was decreased by ANG in HCFs stimulated
with tumor necrosis factor-alpha (TNF-α), and not in those stimulated with lipopolysaccharide (LPS); and the relative mRNA level of IKK-ε was diminished
by ANG in HCFs stimulated either with TNF-α or LPS. b ANG treatment reduced TBK1 protein expression in HCFs stimulated with TNF-α, and not in those
stimulated with LPS, and down-regulated IKK-ε protein expression in HCFs stimulated either with TNF-α or LPS. c Densitometric analysis of the expression
of TBK1 and IKK-ε protein relative to beta-actin in HCFs. The experiments were repeated at least three times. One-way ANOVA followed by Bonferroni’s
post hoc analysis, *p < 0.05
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function of ANG in inflamed HCFs through the reduction
of IKK-ε production suggests a new perspective for inflam-
matory modulation in human corneas.
Scar formation and corneal opacity are important in
corneal inflammation. It is well documented that scar
formation is an abnormal state of wound healing sug-
gesting an excessive activity of fibroblast cells during
wound healing [38]. Moreover, corneal opacity is re-
sulted in wound and downregulated by suppression of
corneal inflammation [39, 40]. Our results reveal that
ANG treatment reduced corneal opacity and scar forma-
tion at the peripheral cornea including conjunctiva. It
can suggest that ANG has a potential to be applied to
corneal inflammatory disorder clinically.
LPS generally leads to inflammation, inducing the release
of pro-inflammatory cytokines and chemokines such as
TNF-α, IL-6, IL-8, MCP-1 and MCP-2 [41, 42]. TNF-α also
causes inflammatory responses producing several pro-
inflammatory cytokines including IL-6, IL-8, and MCP-1
[43, 44]. It is well demonstrated that IL-6 and IL-8 perform
a crucial role in initiating chronic inflammation and, add-
itionally in corneal inflammatory diseases [45–48]. IL-4 and
IL-10 known as the anti-inflammatory cytokines restrain
the immune response and inhibit the expression of pro-
inflammatory cytokines [49]. The noticeable finding in this
study is that the expression of TNF-α, IL-6, IL-8, MCP-1
and MCP-2 induced by TNF-α or LPS was reduced after
ANG treatment. In contrast, the mRNA expression of IL-4
Fig. 7 Western blot and immunocytochemical analyses of nuclear factor-kappaB (NF-κB) in the nucleus and cytoplasm of human corneal fibroblasts
(HCFs) with or without angiogenin (ANG) treatment. a After ANG treatment, nuclear translocation of NF-κB induced by tumor necrosis factor-alpha
(TNF-α) or lipopolysaccharide (LPS) was decreased. b Densitometric analysis of the nuclear expression of NF-κB protein relative to lamin in HCFs. The
experiments were performed in triplicate. One-way ANOVA followed by Bonferroni’s post hoc analysis, *p < 0.05. c Immunocytochemistry of NF-κB in
the nuclei and cytoplasm of HCFs. The intranuclear fluorescence of NF-κB induced by TNF-α or LPS was suppressed by ANG treatment. Scale
bar, 100 μm
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and IL-10 was up-regulated by ANG treatment. On the
basis of these results, we presumed that ANG may have
anti-inflammatory function in suppression of pro-
inflammatory cytokines such as TNF-α, IL-6, IL-8, MCP-1
and MCP-2 in HCFs.
Previously, several reports have suggested that IL-6 reg-
ulates ANG expression [50, 51]. But, interestingly, ANG
treatment induces cytokine production including IL-6 in
this study. It is well documented that ANG activates extra-
cellular signal-regulated kinases (ERK) and causes angio-
genesis and nitric oxide synthesis [52]. Thus, induction of
several cytokines expression could have been occurred by
ANG treatment.
NF-κB is a significant regulator of the immune response
and inflammation. The activation of NF-κB elevated the
expression of inflammatory cytokines and is related with
several inflammatory diseases [53]. Inflammatory responses
induced by LPS or TNF-α via activation of TLR4, MYD88,
TNFR1 or TNFR2 cause NF-κB activation, which is sup-
pressed by IκB proteins including TBK1 and IKK-ε, thus,
isolating NF-κB in the cytoplasm [54]. The complement
activation also causes nuclear translocation of NF-κB [10].
It has been proposed that TBK1 and IKK-ε conduct an es-
sential role in inflammation and the inhibition of TBK1
and IKK-ε is a target for inflammatory diseases [25]. The
inhibitor of complement activation has also been reported
as an anti-inflammatory therapeutic compound [55]. It is
well documented that the inhibitor of complement activa-
tion has the potential of a drug for inflammatory disease
such as arthritis [56]. Our serial results suggest that ANG
may inhibit NF-κB nuclear translocation through a de-
crease in TBK1 and IKK-ε production and inhibition of
TLR4, MYD88, TNFR1, TNFR2, and complement compo-
nent mRNA expression in TNF-α- or LPS-inflamed HCFs.
Corneal alkali burn results in an excessive immune re-
sponse of the cornea inducing corneal opacity and neovas-
cularization [57]. Because it was shown that ANG reduced
corneal opacity and neovascularization in corneal alkali
burn in this study, it is expected that ANG can suppress
the immune-mediated inflammatory responses in chemical
burns of the eye as verified in an in vitro analysis. Add-
itionally, although ANG is also known as a stimulator of
new vessel formation through the process of angiogenesis,
ANG treatment did not cause any adverse effect such as
injection on the ocular surface. We expect that ANG has
the potential as a therapeutic molecule against ocular in-
flammatory diseases.
The schematic diagram illustrating the anti-inflammatory
signaling pathways induced by ANG in TNF-α- or LPS-
inflamed HCFs is shown in Fig. 8. Inflammatory signal
Fig. 8 Schematic model illustrating the signaling pathway by which angiogenin (ANG) reduces the inflammatory responses involving TANK-binding kinase
(TBK)1- and IkappaB kinase-epsilon (IKK-ε)-mediated nuclear translocation of nuclear factor-kappaB (NF-κB) in tumor necrosis factor-alpha (TNF-α)- or
lipopolysaccharide (LPS)-induced inflammatory human corneal fibroblasts (HCFs). ANG down-regulates the mRNA expression of pro-inflammatory cytokines
(interleukin [IL]-1β, IL-6 and IL-8) and up-regulates the mRNA expression of anti-inflammatory cytokines (IL-4 and IL-10). ANG suppresses the nuclear
translocation of NF-κB through the inhibition of TNF-α receptor (TNFR)1 and TNFR2 mRNA expression and TBK1 production in TNF-α-induced inflammatory
HCFs. ANG also reduces NF-κB nuclear translocation through a reduction in toll-like receptor (TLR)4 and myeloid differentiation primary response gene
(MYD)88 mRNA expression and IKK-ε expression in LPS-induced inflammatory HCFs. The cascade underlying the effect of ANG results in a suppression of
inflammatory cytokines and chemokines such as TNF-α, monocyte chemotactic protein (MCP)-1, MCP-2, IL-6 and IL-8
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induced by TNF-α or LPS is triggered via TLR4, MYD88,
TNFR1, and TNFR2. The inflammatory response induces
TBK1 and IKK-ε activation and mediates nuclear transloca-
tion of NF-κB. The mRNA expression of IL-1β, IL-6 and
IL-8 is reduced by ANG and ANG treatment increases the
mRNA expression of IL-4 and IL-10. ANG also inhibits the
nuclear translocation of NF-κB through suppression of
TBK1 and IKK-ε production. The anti-inflammatory effect
induced by ANG eventually causes a decrease in the ex-
pression of pro-inflammatory cytokines and chemokines
such as IL-6, IL-8, MCP-1, MCP-2, and TNF-α.
Although ANG treatment did not cause adverse effect
such as injection on the ocular surface, in vivo animal stud-
ies conducted over a long term are required to further
confirm the clinical application of ANG in corneal inflam-
mation to eliminate the doubt of possible adverse effect. In
a future study, the cytokine analysis to detect the reduction
of pro-inflammatory cytokines in corneal stroma, tear fluids
or aqueous humor and NF-κB suppression through the in-
hibition of IKK-ε may be required to confirm the anti-
inflammatory activity of ANG in in vivo animal studies and
to clarify the ANG-specific regulation of inflammation.
Moreover, further study is needed to confirm ANG activity
through comparison of anti-inflammatory effect between
ANG and other drug such as steroids.
Conclusion
The role of ANG in the inflammatory response has been
little investigated. The finding of suppression of IKK-ε pro-
duction by ANG in HCFs established in this investigation
indicates that ANG can reduce the immune responses and
corneal inflammation. Our results demonstrated that ANG
down-regulated the inflammatory response triggered by
NF-κB activation via inhibition of IKK-ε expression in
TNF-α- or LPS-induced inflammatory HCFs. This study
showing the anti-inflammatory effect of ANG proposes that
ANG has a novel therapeutic potential against corneal
inflammation.
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